10月19日，Iovance Biotherapeutics盘中上涨5.36%，报14.535美元/股，成交额1608.62万美元。
消息面上，公司宣布将在欧洲肿瘤医学学会大会重点展示跨实体瘤TIL细胞治疗平台，并将以两场口头报告公布一线黑色素瘤及经治非小细胞肺癌中的深度、持久缓解数据，强化市场对其实体瘤细胞疗法商业化与适应症拓展前景的关注。
公司此前还将全年营收指引上调至4.10亿至4.20亿美元，高于原先的3.50亿至3.70亿美元，显示Amtagvi与Proleukin需求改善，为此次股价异动提供基本面支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.